Skip to content
DataLookout
Menu

NCT04715646

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 40 versions: 36 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 13 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Trial sites reduced: 36 → 32 locations
    • Final enrollment: 84 participants (planned 70)
    • Study description revised
  2. Minor Study sites: 34 to 36v38
  3. Notable Primary and study completion dates: Jul 17, 2029 to Jul 8, 2030v37
  4. Notable Trial status: Active, Not Recruiting to Recruiting
    • Study sites: 30 to 34
    v36
  5. Minor Study sites: 29 to 30v35
Show 30 earlier versionsHide 30 earlier versions
  1. Minor Study sites: 27 to 29v34
  2. Minor Study sites revised (27)v33
  3. Minor Study sites: 26 to 27v32
  4. Notable Primary and study completion dates: Jul 17, 2025 to Jul 17, 2029v29
  5. Minor Site details revised at 1 of 26 sitesv27
  6. Minor Site details revised at 1 of 26 sitesv26
  7. Minor Study sites: 27 to 26v25
  8. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 79 to confirmed 70
    • Study sites: 31 to 27
    • Primary and study completion dates: Jul 2, 2025 to Jul 17, 2025
    v24
  9. Minor Study sites: 30 to 31v23
  10. Minor Primary and study completion dates: May 2, 2025 to Jul 2, 2025v22
  11. Notable Eligibility criteria shortened, about 206 wordsv21 Show 5 more changesShow less
    • Enrollment target: 100 to 79
    • Primary and study completion dates: May 2025 to May 2, 2025
    • Study description shortened, about 25 words
    • Site details revised at 4 of 30 sites
    • Study title revised
  12. Minor Site details revised at 1 of 30 sitesv20
  13. Minor Study sites: 29 to 30v19
  14. Minor Primary and study completion dates: Apr 2025 to May 2025
    • Site details revised at 4 of 29 sites
    v18
  15. Minor Site details revised at 12 of 29 sitesv17
  16. Minor Study sites: 27 to 29v16
  17. Minor Study sites: 26 to 27v15
  18. Minor Study sites: 24 to 26v14
  19. Minor Study sites: 23 to 24v13
  20. Minor Study sites: 22 to 23v12
  21. Minor Study sites: 21 to 22v11
  22. Minor Study sites: 20 to 21v10
  23. Minor Study sites: 17 to 20v9
  24. Minor Study sites: 15 to 17v8
  25. Minor Study sites: 12 to 15v7
  26. Minor Study sites: 9 to 12v6
  27. Minor Study sites: 7 to 9v5
  28. Minor Study sites: 4 to 7v4
  29. Minor Study sites: 1 to 4v3
  30. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 2021 to Mar 11, 2021
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of treatment-emergent adverse events (TEAEs) during the study
Timeframe: From Evaluation Visit (Day 1) until Safety Visits (up to 5 years)
Incidence of treatment-emergent serious adverse events (SAEs) during the study
Timeframe: From Evaluation Visit (Day 1) until Safety Visits (up to 5 years)
Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of study drug during the study
Timeframe: From Evaluation Visit (Day 1) until Safety Visits (up to 5 years)

Arms and interventions

BrivaracetamExperimental

LTFU study participants: Up to 5mg/kg/day (for study participants weighing 11kg to less than 20kg) and up to 4mg/kg/day (for study participants weighing 20kg to less than 50kg) and no more than 200mg/day Directly enrolled (DE) study participants: 1mg/kg/day to 4mg/kg/day and no more than 200mg/day.

Drugs: Brivaracetam

Sites

32 sites in 7 countries

Japan 19, Hungary 3, Mexico 3, Poland 3, United States 2, Italy 1, Spain 1